The Experts below are selected from a list of 2760 Experts worldwide ranked by ideXlab platform
Anna Pomes - One of the best experts on this subject based on the ideXlab platform.
-
recombinant Allergens for diagnosis and therapy of allergic disease
The Journal of Allergy and Clinical Immunology, 2000Co-Authors: Martin D Chapman, Alisa M Smith, Lisa D Vailes, Karla L Arruda, V Dhanaraj, Anna PomesAbstract:Many of the problems associated with using natural Allergenic products for allergy diagnosis and treatment can be overcome with use of genetically engineered recombinant Allergens. Over the past 10 years, the most important Allergens from mites, pollens, animal dander, insects, and foods have been cloned, sequenced, and expressed. In many cases the three-dimensional Allergen Structure has been determined and B-cell and T-cell epitopes have been mapped. These studies show that Allergens have diverse biologic functions (they may be enzymes, enzyme inhibitors, lipocalins, or structural proteins) and that as a rule the Allergen function is unrelated to its ability to cause IgE antibody responses. High-level expression systems have been developed to produce recombinant Allergens in bacteria, yeast, or insect cells. Recombinant Allergens show comparable IgE antibody binding to their natural counterparts (where available) and show excellent reactivity on skin testing and in in vitro diagnostic tests. Cocktails of recombinant Allergens can be formulated with predetermined and uniform Allergen levels, which could replace natural Allergens and result in the development of innovative, patient-based tests for allergy diagnosis. Recombinant Allergens also offer the exciting possibility of developing new forms of Allergen immunotherapy, including the use of hypoAllergens, Allergens coupled to IgE suppressive adjuvants, and peptide-based therapies. The production of recombinant Allergens as defined molecular entities makes it feasible to consider the possibility of developing prophylactic Allergen vaccines. The introduction of recombinant Allergens in research and in clinical trials should lead to significant improvements in allergy diagnosis and treatment.
Wesley A Burks - One of the best experts on this subject based on the ideXlab platform.
-
peptide and recombinant Allergen vaccines for food allergy
Clinical Reviews in Allergy & Immunology, 2018Co-Authors: Quindelyn Cook, Wesley A BurksAbstract:Food allergy is a significant public health problem, with no suitable treatments available for patients. Currently, patients are limited to avoidance and the use of readily available emergency medications. Immunotherapy is an appealing therapeutic strategy for inducing tolerance. Studies with whole native Allergens have demonstrated the efficacy of immunotherapy for food allergy; however, the risk of IgE-mediated reactions with such treatment is significant. Advances in molecular biology techniques, including purification, sequencing, and cloning, have allowed researchers to identify specific Allergen components and T cell binding epitopes. Support for the use of recombinant and peptide vaccines for food allergy comes from prior studies involving aeroAllergens and hymenoptera venom. By manipulating Allergen Structure and IgE binding, Allergenicity can be reduced, thereby reducing systemic reactions, making recombinant and peptide vaccines a safe and effective form of immunotherapy. Pre-clinical studies using in vitro and murine models demonstrated a more tolerant state following the use of these therapies. Studies with human subjects will be necessary to characterize the effects of recombinant and peptide food allergy vaccines and to demonstrate a safe treatment option for patients.
-
protein Structure plays a critical role in peanut Allergen stability and may determine immunodominant ige binding epitopes
Journal of Immunology, 2002Co-Authors: Moon Sen, Wesley A Burks, Randall A Kopper, L Pons, Edathara C Abraham, Gary A BannonAbstract:Hypersensitivity to peanuts is a reaction mediated by IgE Abs in response to several peanut protein Allergens. Among these Allergenic proteins, Ara h 2 is one of the most commonly recognized Allergens. Ara h 2 is a 17-kDa protein that has eight cysteine residues that could form up to four disulfide bonds. Circular dichroism studies showed substantial changes in the secondary and tertiary Structures of the reduced Ara h 2 as compared with the native protein. Upon treatment with trypsin, chymotrypsin, or pepsin, a number of relatively large fragments are produced that are resistant to further enzymatic digestion. These resistant Ara h 2 peptide fragments contain intact IgE-binding epitopes and several potential enzyme cut sites that are protected from the enzymes by the compact Structure of the protein. The enzyme-treated Allergen remains essentially intact despite the action of proteases until the fragments are dissociated when the disulfide linkages are reduced. Amino acid sequence analysis of the resistant protein fragments indicates that they contain most of the immunodominant IgE-binding eptiopes. These results provide a link between Allergen Structure and the immunodominant IgE-binding epitopes within a population of food-allergic individuals.
Martin D Chapman - One of the best experts on this subject based on the ideXlab platform.
-
recombinant Allergens for diagnosis and therapy of allergic disease
The Journal of Allergy and Clinical Immunology, 2000Co-Authors: Martin D Chapman, Alisa M Smith, Lisa D Vailes, Karla L Arruda, V Dhanaraj, Anna PomesAbstract:Many of the problems associated with using natural Allergenic products for allergy diagnosis and treatment can be overcome with use of genetically engineered recombinant Allergens. Over the past 10 years, the most important Allergens from mites, pollens, animal dander, insects, and foods have been cloned, sequenced, and expressed. In many cases the three-dimensional Allergen Structure has been determined and B-cell and T-cell epitopes have been mapped. These studies show that Allergens have diverse biologic functions (they may be enzymes, enzyme inhibitors, lipocalins, or structural proteins) and that as a rule the Allergen function is unrelated to its ability to cause IgE antibody responses. High-level expression systems have been developed to produce recombinant Allergens in bacteria, yeast, or insect cells. Recombinant Allergens show comparable IgE antibody binding to their natural counterparts (where available) and show excellent reactivity on skin testing and in in vitro diagnostic tests. Cocktails of recombinant Allergens can be formulated with predetermined and uniform Allergen levels, which could replace natural Allergens and result in the development of innovative, patient-based tests for allergy diagnosis. Recombinant Allergens also offer the exciting possibility of developing new forms of Allergen immunotherapy, including the use of hypoAllergens, Allergens coupled to IgE suppressive adjuvants, and peptide-based therapies. The production of recombinant Allergens as defined molecular entities makes it feasible to consider the possibility of developing prophylactic Allergen vaccines. The introduction of recombinant Allergens in research and in clinical trials should lead to significant improvements in allergy diagnosis and treatment.
Alisa M Smith - One of the best experts on this subject based on the ideXlab platform.
-
recombinant Allergens for diagnosis and therapy of allergic disease
The Journal of Allergy and Clinical Immunology, 2000Co-Authors: Martin D Chapman, Alisa M Smith, Lisa D Vailes, Karla L Arruda, V Dhanaraj, Anna PomesAbstract:Many of the problems associated with using natural Allergenic products for allergy diagnosis and treatment can be overcome with use of genetically engineered recombinant Allergens. Over the past 10 years, the most important Allergens from mites, pollens, animal dander, insects, and foods have been cloned, sequenced, and expressed. In many cases the three-dimensional Allergen Structure has been determined and B-cell and T-cell epitopes have been mapped. These studies show that Allergens have diverse biologic functions (they may be enzymes, enzyme inhibitors, lipocalins, or structural proteins) and that as a rule the Allergen function is unrelated to its ability to cause IgE antibody responses. High-level expression systems have been developed to produce recombinant Allergens in bacteria, yeast, or insect cells. Recombinant Allergens show comparable IgE antibody binding to their natural counterparts (where available) and show excellent reactivity on skin testing and in in vitro diagnostic tests. Cocktails of recombinant Allergens can be formulated with predetermined and uniform Allergen levels, which could replace natural Allergens and result in the development of innovative, patient-based tests for allergy diagnosis. Recombinant Allergens also offer the exciting possibility of developing new forms of Allergen immunotherapy, including the use of hypoAllergens, Allergens coupled to IgE suppressive adjuvants, and peptide-based therapies. The production of recombinant Allergens as defined molecular entities makes it feasible to consider the possibility of developing prophylactic Allergen vaccines. The introduction of recombinant Allergens in research and in clinical trials should lead to significant improvements in allergy diagnosis and treatment.
Lisa D Vailes - One of the best experts on this subject based on the ideXlab platform.
-
recombinant Allergens for diagnosis and therapy of allergic disease
The Journal of Allergy and Clinical Immunology, 2000Co-Authors: Martin D Chapman, Alisa M Smith, Lisa D Vailes, Karla L Arruda, V Dhanaraj, Anna PomesAbstract:Many of the problems associated with using natural Allergenic products for allergy diagnosis and treatment can be overcome with use of genetically engineered recombinant Allergens. Over the past 10 years, the most important Allergens from mites, pollens, animal dander, insects, and foods have been cloned, sequenced, and expressed. In many cases the three-dimensional Allergen Structure has been determined and B-cell and T-cell epitopes have been mapped. These studies show that Allergens have diverse biologic functions (they may be enzymes, enzyme inhibitors, lipocalins, or structural proteins) and that as a rule the Allergen function is unrelated to its ability to cause IgE antibody responses. High-level expression systems have been developed to produce recombinant Allergens in bacteria, yeast, or insect cells. Recombinant Allergens show comparable IgE antibody binding to their natural counterparts (where available) and show excellent reactivity on skin testing and in in vitro diagnostic tests. Cocktails of recombinant Allergens can be formulated with predetermined and uniform Allergen levels, which could replace natural Allergens and result in the development of innovative, patient-based tests for allergy diagnosis. Recombinant Allergens also offer the exciting possibility of developing new forms of Allergen immunotherapy, including the use of hypoAllergens, Allergens coupled to IgE suppressive adjuvants, and peptide-based therapies. The production of recombinant Allergens as defined molecular entities makes it feasible to consider the possibility of developing prophylactic Allergen vaccines. The introduction of recombinant Allergens in research and in clinical trials should lead to significant improvements in allergy diagnosis and treatment.